Skip to Content

Ustekinumab Dosage

Medically reviewed on September 3, 2018.

Applies to the following strengths: 5 mg/mL; 45 mg/0.5 mL; 90 mg/mL

Usual Adult Dose for Plaque Psoriasis

100 kg or less:
Initial dose: 45 mg subcutaneously initially and 4 weeks later
Maintenance dose: 45 mg subcutaneously every 12 weeks

Greater than 100 kg:
Initial dose: 90 mg subcutaneously initially and 4 weeks later
Maintenance dose: 90 mg subcutaneously every 12 weeks

Comments:
-In subjects weighing greater than 100 kg, 45 mg was also shown to be effective; however, 90 mg resulted in greater efficacy.

Use: For moderate to severe plaque psoriasis (Ps) in patients who are candidates for phototherapy or systemic therapy

Usual Adult Dose for Psoriatic Arthritis

Initial dose: 45 mg subcutaneously initially and 4 weeks later
Maintenance dose: 45 mg subcutaneously every 12 weeks

For patients with co-existent moderate-to-severe plaque psoriasis weighing greater than 100 kg:
Initial dose: 90 mg subcutaneously initially and 4 weeks later
Maintenance dose: 90 mg subcutaneously every 12 weeks

Use: For patients with active psoriatic arthritis (PsA) alone or in combination with methotrexate (MTX)

Usual Adult Dose for Crohn's Disease - Acute

Initial dose:
-Up to 55 kg: 260 mg IV
-Greater than 55 kg to 85 kg: 390 mg IV
-Greater than 85 kg: 520 mg IV

Maintenance dose (all weight ranges): 90 mg subcutaneously 8 weeks after the initial dose and every 8 weeks thereafter

Use: For patients with moderately to severely active Crohn's disease (CD) who have:
-Failed or were intolerant to therapy with immunomodulators or corticosteroids, but never failed a tumor necrosis factor (TNF) blocker
OR
-Failed or were intolerant to therapy with one or more TNF blockers

Usual Adult Dose for Crohn's Disease - Maintenance

Initial dose:
-Up to 55 kg: 260 mg IV
-Greater than 55 kg to 85 kg: 390 mg IV
-Greater than 85 kg: 520 mg IV

Maintenance dose (all weight ranges): 90 mg subcutaneously 8 weeks after the initial dose and every 8 weeks thereafter

Use: For patients with moderately to severely active Crohn's disease (CD) who have:
-Failed or were intolerant to therapy with immunomodulators or corticosteroids, but never failed a tumor necrosis factor (TNF) blocker
OR
-Failed or were intolerant to therapy with one or more TNF blockers

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-It is recommended that each injection be administered at a different anatomic location (such as upper arms, gluteal regions, thighs, or any quadrant of the abdomen) than the previous injection, and not into areas where the skin is tender, bruised, erythematous, or indurated.
-Patients may self-administer injections after training in subcutaneous injection technique.

General:
-The needle cover on the prefilled syringe contains dry natural rubber (a derivative of latex). The needle cover should not be handled by persons sensitive to latex.
-Prior to administration, the product should be inspected for particulate matter and discoloration. It should be clear, colorless to light yellow and may contain a few small translucent or white particles.
-The product does not contain preservatives; therefore, discard any unused product remaining in the vial and/or syringe.

Storage requirements:
-Refrigerate (2C to 8C); do not freeze.
-Keep prefilled syringe in outer carton to protect from light.

General:
-Each prefilled syringe is for single use only; any unused product should be disposed of in accordance with local guidelines.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide